Literature DB >> 8379692

Enhanced procoagulant activity of mononuclear leukocytes in patients with atopic dermatitis and psoriasis.

R E Schopf1, H Weber, B Morsches.   

Abstract

Fibrin deposition is an important histopathological feature of inflammatory skin lesions and is mediated in part, by procoagulants generated by mononuclear leucocytes (MNL). We examined whether MNL from patients with atopic dermatitis or psoriasis generate enhanced procoagulant activity (PCA). MNL isolated from the peripheral blood of 15 healthy control individuals, 15 patients with atopic dermatitis and 15 patients with psoriasis were incubated for 24 h in the presence or absence of bacterial lipopolysaccharide (LPS). MNL or the cell culture supernatants were then added to recalcified human plasma to determine the clotting time. We found that in both atopic dermatitis and psoriasis MNL cultured in the presence or absence of LPS expressed greatly enhanced PCA (p < 0.01 to < 0.002). Supernatants from MNL cultures from patients with psoriasis, but not those from patients with atopic dermatitis, also generated augmented PCA (p < 0.002). In psoriasis, PCA normalized after successful topical treatment with anthralin. We conclude that enhanced PCA is a characteristic feature of MNL in both atopic dermatitis and psoriasis. In psoriasis the enhanced PCA is directly related to disease activity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8379692     DOI: 10.1007/bf00371602

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  40 in total

1.  Leukocyte procoagulant activity: enhancement of production in vitro by IgG and antigen-antibody complexes.

Authors:  H Rothberger; T S Zimmerman; H L Spiegelberg; J H Vaughan
Journal:  J Clin Invest       Date:  1977-03       Impact factor: 14.808

Review 2.  Immunoregulatory abnormalities in atopic dermatitis.

Authors:  D Y Leung; R S Geha
Journal:  Clin Rev Allergy       Date:  1986-02

3.  Cyclosporin A for psoriasis.

Authors:  W Mueller; B Herrmann
Journal:  N Engl J Med       Date:  1979-09-06       Impact factor: 91.245

4.  Anthralin toxicity.

Authors:  M W Gay; W J Moore; J M Morgan; L F Montes
Journal:  Arch Dermatol       Date:  1972-02

5.  Lipid A as the biologically active moiety in bacterial endotoxin (LPS)-initiated generation of procoagulant activity by peripheral blood leukocytes.

Authors:  J Niemetz; D C Morrison
Journal:  Blood       Date:  1977-06       Impact factor: 22.113

6.  Morphological and functional findings of fixed phagocytes in psoriatics.

Authors:  P Altmeyer; D L Munz; G Chilf; H Holzmann; G Hör
Journal:  Arch Dermatol Res       Date:  1983       Impact factor: 3.017

7.  Delayed hypersensitivity in man: effects of systemic anticoagulation.

Authors:  R L Edwards; F R Rickles
Journal:  Science       Date:  1978-05-05       Impact factor: 47.728

8.  Increased production and expression of tissue thromboplastin-like procoagulant activity in vitro by allogeneically stimulated human leukocytes.

Authors:  H Rothberger; T S Zimmerman; J H Vaughan
Journal:  J Clin Invest       Date:  1978-09       Impact factor: 14.808

9.  Enhanced releasability of prostaglandin E2 and leukotrienes B4 and C4 from leukocytes of patients with atopic eczema.

Authors:  T Ruzicka; J Ring
Journal:  Acta Derm Venereol       Date:  1987       Impact factor: 4.437

10.  Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration.

Authors:  M Clauss; M Gerlach; H Gerlach; J Brett; F Wang; P C Familletti; Y C Pan; J V Olander; D T Connolly; D Stern
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

View more
  1 in total

1.  Chemical Modulators of Fibrinogen Production and Their Impact on Venous Thrombosis.

Authors:  Rui Vilar; Samuel W Lukowski; Marco Garieri; Corinne Di Sanza; Marguerite Neerman-Arbez; Richard J Fish
Journal:  Thromb Haemost       Date:  2020-12-10       Impact factor: 5.249

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.